We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This study has been withdrawn prior to enrollment.
(Gallium is no longer available for the conduct of this study.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00836173
First Posted: February 4, 2009
Last Update Posted: March 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genta Incorporated
Information provided by (Responsible Party):
Scott E Smith, MD, PhD, Loyola University
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: May 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)